EQUALstudy@dfci.harvard.edu (857) 215-2794 Login

Our Team

Meet the researchers, clinicians, and community partners behind the EQUAL Study.

EQUAL Team

Narjust Florez, MD

Principal Investigator, DFCI
Thoracic Medical Oncologist
Associate Director, Cancer Care Equity Program
Assistant Professor of Medicine, Harvard Medical School

David Barbie, MD

Co-Investigator, DFCI
Thoracic Medical Oncologist
Director, Lowe Center for Thoracic Oncology
Associate Director, Belfer Center for Applied Cancer Research

Cloud Paweletz, PhD

Co-Investigator, DFCI
Head of Research, Belfer Center for Applied Cancer Research

Lilin Tong, BS

Medical Student, BUSM

Erin Soulia

Regulatory Coordinator, DFCI

Fernando Pacheco

Research Data Specialist, DFCI

Kylee Coonradt

Research Data Specialist, DFCI

Yanan Kuang, PhD

Senior Scientist, DFCI
Blood-based Biomarker Lead, Belfer Center for Applied Cancer Research

Shidong (Sheridan) Xu

Senior Research Associate
Belfer Center for Applied Cancer Science
Dana-Farber Cancer Institute

Collaborators

Lecia Sequist, MD, MPH

Co-Investigator, MGH
Director, Cancer Early Detection and Diagnostics Clinic
Landry Family Professor of Medicine, Harvard Medical School

Daniel Costa, MD, PhD

Co-Investigator, BIDMC
Medical Oncologist, BIDMC
Professor of Medicine, Harvard Medical School

Shail Maingi, MD

Co-Investigator, DFCI South Shore
Medical Oncologist, DFCI South Shore

Alys Malcolm, MD

Co-Investigator, DFCI St. Elizabeth's
Medical Oncologist & Medical Director, DFCI St. Elizabeth's Medical Center

Pedro Sanz, MD, PhD

Co-Investigator, DFCI Merrimack Valley
Medical Oncologist, DFCI Merrimack Valley

Taylor Ortiz, MD

Co-Investigator, DFCI Merrimack Valley
Medical Oncologist & Medical Director, DFCI Merrimack Valley

Community Partners

This study prioritizes the development of lasting relationships with East Asian and Latinx/Hispanic populations through community partnership and integration of the direct patient voice to not only enhance recruitment efforts of this study and its future iterations, but also to foster trust and increase willingness to participate in future cancer research and interventions.